Current issues in treating the hypertensive patient with diabetes: Focus on diabetic nephropathy

Annals of Pharmacotherapy

Volumn 30, Issue 7-8, 1996, Pages 791-801

  Cziraky, Mark J ^a,b   Mehra, Ila V ^c   Wilson, Marcus D ^d,e   Bakris, George L ^f  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b HealthCare Center at Christiana   (United States)

^c ST LOUIS COLLEGE OF PHARMACY   (United States)

^d Philadelphia Coll Pharm and Sci   (United States)

^e Healthcare Center   (United States)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LISINOPRIL; LOSARTAN; METOPROLOL; PRAZOSIN; THIAZIDE DIURETIC AGENT; VERAPAMIL;

ALGORITHM; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HYPERTENSION; HYPOKALEMIA; IMPOTENCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY FAILURE; LIPID METABOLISM; PRIORITY JOURNAL; PROTEINURIA; REVIEW;

EID: 0030037381     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000718     Document Type: Review

References (81)

1. Houston MC. Treatment of hypertension in diabetes mellitus. Am Heart J 1989;118:819-29.
2. American Diabetes Association Consensus Statement. Treatment of hypertension in diabetes. Diabetes Care 1993;16:1394-401.
3. Houston MC. Coexistent hypertension and diabetes: therapeutic recommendations. Primary Cardiol 1992;18(2):80-91.
4. Joint National Committee. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressures. Arch Intern Med 1993;153:154-83.
5. Tuck M. Management of hypertension in the patient with diabetes mellitus: focus on the use of angiotensin-converting enzyme inhibitors. Am J Hypertens 1988;1(suppl):384-8S.
6. Valentine VA, Wilson MD, Weart W, Bakris GL. A perspective on converting enzyme inhibitors and calcium channel antagonists in diabetic renal disease. Arch Intern Med 1991;151:2367-72.
7. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in type I diabetes. Am J Med 1985;78:785-94.
8. Christlieb AR, Kaldany A, D'Elia JA, Williams GH. Aldosterone responsiveness in patients with diabetes mellitus. Diabetes 1978;27:732-7.
9. Bakris GL. Pathogenesis of hypertension in diabetics. Diabetes Rev (in press).
10. Modan M, Halkin H, Almog S, Lusky A, Esckol A, Shefi M. Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Invest 1985;75:809-17.
11. Christlieb AR, Krolewski AS, Warram JH, Soeldner JS. Is insulin the link between hypertension and obesity? Hypertension 1985;7(6 pt 2): 1154-7.
12. Young JB, Landsberg L. Diet-induced changes in sympathetic nervous system activity: possible implications for obesity and hypertension. J Chron Dis 1982;35:879-86.
13. Gerber LM, Scmukler C, Alderman MH. Differences in urinary albumin excretion rate between normotensive and hypertensive, white and non-white subjects. Arch Intern Med 1992;152:373-7.
14. National High Blood Pressure Education Program (NHBPEP) Working Group. The NHBPEP Working Group report on hypertension and chronic renal failure. Arch Intern Med 1991;151:1280-7.
15. Parving HH, Smidt UM, Hommel E, Mathieson ER, Rossing P, Neilson F, et al. Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am J Kidney Dis 1993;22:188-95.
16. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984;310:356-60.
17. Mattock MB, Marrish NJ, Viberti G, Keen H, Fitzgerald AP, Jackson G. Prospective study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes 1992;41:736-41.
18. Abbott KC, Sauderg L, Bakris GL. Microalbuminuria in type II diabetes: implications for renal survival. Arch Intern Med 1993;154:146-52.
19. National High Blood Pressure Education Program (NHBPEP) Working Group. The NHBPEP working group report on hypertension in diabetes. Hypertension 1994;23:145-58.
20. Klein R, Klein BEK, Moss SE, Davis ME, DeMets D. The Wisconsin epidemiology study of diabetic retinopathy D: prevalence and risk of diabetic retinopathy when eye at diagnosis is less than 30 years. Arch Ophthalmol 1984;102:520-9.
21. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease with emphasis on the stage of incipient diabetic nephropathy. Diabetes 1983;32(suppl 2):64-78.
22. Selby JV, Fitzsimmons SC, Newman JM, Katz PP, Sepe S, Showstack J. The natural history and epidemiology of diabetic nephropathy. JAMA 1990;263:1954-60.
23. Hoelscher DD, Weir MR, Bakris GL. Hypertension in diabetic patients: an update of interventional studies to preserve renal function. J Clin Pharm 1995;35:73-80.
24. Brancati FL, Whittle JC, Whelton PK, Seidler AJ, Klag MJ. The excess incidence of diabetic end-stage renal disease among blacks: a population-based study of potential explanatory factors. JAMA 1992;268:3079-84.
25. Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med 1989;321:1074-9.
26. Christlieb AR. Treatment selection considerations for the hypertensive diabetic patient. Arch Intern Med 1990;(150c-6):1167-74.
27. Christensen JS, Gammelgaard J, Tronier B, Svender PA, Parving HH. Kidney function and size in diabetics before and during initial insulin treatment. Kidney Int 1982;21:683-8.
28. Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts diminished pregression in diabetic nephropathy. Kidney Int 1994;45(suppl 45):S145-9.
29. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118:577-81.
30. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int 1992; 41:912-9.
31. Lewis EJ, Hunsicker LG, Bain RP, Rhode RD. The effect of angiotensin converting enzyme inhibition in diabetic nephropathy. N Engl J Med 1993;323:1456-62.
32. Bakris GL. Angiotensin-converting enzyme inhibitors and progression of diabetic nephropathy. Ann Intern Med 1993;118:643-4.
33. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC. Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984;74:1143-55.
34. Bakris GL, Williams B. Angiotensin-wconverting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ? J Hypertens 1995;13(suppl):S95-102.
35. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994;45:861-7.
36. Anderson S, Rennke HG, Zatz R. Glomerular adaptations with normal aging and with long-term converting inhibition in rats. Am J Physiol 1994;267(suppl):F35-43.
37. Myers BD. Pathophysiology of proteinuria in diabetic glomerular disease. J Hypertens 1990;8(suppl):S41-6.
38. Maki DD, Ma JZ, Louis TA, Kaisiske BL. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995;155:1073-80.
39. Bakris GL. Hypertension in diabetic patients: an overview of interventional studies to preserve renal function. Am J Hypertens 1993;6(suppl): 140-7s.
40. Hartmann A, Lund K, Holdaas H, Fauchald P, Reisaeter A, Berg KJ. Contrasting short-term effects of nifedipine on glomerular and tubular functions in glomerular nephritic patients. Am Soc Nephrol 1994;5: 1385-90.
41. Gaber L, Walton C, Brown S, Bakris G. Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int 1994;46:161-9.
42. Slataper R, Vicknair N, Sadler R, Bakris GL. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med 1993;153:973-80.
43. National High Blood Pressure Educational Program (NHBPEP) Working Group. The NHBPEP Working Group report on primary prevention of hypertension. Arch Intern Med 1993;153:186-208.
44. Heeg JE, de Jong PE, Vander Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinemic effect of ACE inhibition by lisinopril. Kidney Int 1989;36:272-9.
45. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
46. American Diabetes Association, National Kidney Foundation. Consensus development conference on the diagnosis and management of nephropathy in patients with diabetes mellitus. Diabetes Care 1994;17: 1357-61.
47. Berne C, Pollare T, Lithell H. Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE-inhibitors. Diabetes Care 1991;14(suppl 4):39-47.
48. Torlone E, Rambotti AM, Perriello G, Botta G, Santeusanio F, Brunetti P, et al. ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with type II (non-insulin dependent) diabetes mellitus and arterial hypertension. Diabetalogia 1991;34:119-25.
49. Prince MJ, Stuart CA, Padia M, Bandi Z, Holland OB. Metabolic effects of hydrochlorothiazide and enalapril during treatment of the hypertensive diabetic patient. Enalapril for hypertensive diabetics. Arch Intern Med 1988;148:2363-8.
50. Takasaki I, Shionoiri H, Hiroto S, Yasuda G, Gotoh E, Umemura S, et al. Long-term captopril therapy with no effect on glucose metabolism in patients with essential hypertension. Am J Hypertens 1988;1(suppl): S217-20.
51. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989;321:868-73.
52. Viberti G, Mogensen CE, Groop LC, Pauls JF. European Microalbuminuria Captopril Study: effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994;271:275-9.
53. Baba T, Ishizaki T. Recent advances in pharmacological management of hypertension in diabetic patients with nephropathy: effects of antihypertensive drugs on kidney function and insulin sensitivity. Drugs 1992;43: 464-89.
54. Chellingsworth MC, Kendall MJ, Wright AD, Singh BM, Pasi J. The effects of verapamil, diltiazem, nifedipine and propranolol on metabolic control in hypertensives with NIDDM. J Hum Hypertens 1989;3:35-9.
55. Caldwell BV. Treating hypertension in the diabetic patient: therapeutic goals and the role of calcium channel blockers. Clin Ther 1993;15:618-36.
56. Capewell S, Collier A, Matthews D, Hajducka C, Collier R, Clarke BF, et al. A trial of the calcium antagonist felodipine in hypertensive type-2 diabetic patients. Diabetic Med 1989;6:809-12.
57. Veenstra J, van der Hulst JP, Wildenborg IH, Njoo SF, Verdegall WP, Silberbusch J. Effect of antihypertensive drugs on insulin absorption. Diabetes Care 1991;14:1089-92.
58. Bakris GL. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 1990;122;701-2.
59. Mimran A, Insua A, Ribstein J, Monnier L, Bringer J, Mirouse J. Contrasting effects captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. J Hypertens 1988;6:919-23.
60. Diamond JR, Cheung JY, Fang LS. Nifedipine-induced renal dysfunction. Am J Med 1984;77:905-9.
61. Demarie BK, Bakris GL. Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Intern Med 1990;113: 987-8.
62. Brown SA, Walton CL, Crawford P, Bakris GL. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int 1993;43:1210-8.
63. Kaplan NM. Clinical hypertension. 6th ed. Baltimore, MD: Williams and Wilkins Co., 1994:260-2.
64. Hupponen R, Lehtonen A, Vahatalo M. Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients. Eur J Clin Pharmacol 1992;43:365-8.
65. Lithell HOL. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991;14:203-9.
66. Pollare T, Lithell H, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988;31:415-20.
67. Lehtonen A. Doxazosin effects on insulin and glucose in hypertensive patients. The Finnish Multicenter Study Group. Am Heart J 1991;121(4 part 2):1307-11.
68. Prisant LM, Carr AA. Antihypertensive drug therapy and insulin resistance. Am J Hypertens 1992;5:775-7.
69. Harrower ADB, McFarlane G. Antihypertensive therapy in diabetic patients: the use of indapamide. Am J Med 1988;84(suppl 1B):89-91.
70. Brass EP. Effects of antihypertensive drugs on endocrine function. Drugs 1984;27:447-58.
71. Gambardella S, Frontini S, Felici MG, Spallone V, Garguilo P, Mornano S, et al. Efficacy of antihypertensive treatment with indapamide in patients with non-insulin-dependent diabetes and persistent microalbuminuria. Am J Cardiol 1990;65(suppl):46-50H.
72. Groop L, Totterman KJ, Harno K, Gordin A. Influence of beta-blocking drugs on glucose metabolism in patients with non-insulin-dependent diabetes mellitus. Acta Med Scand 1982;211:7-12.
73. Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double-blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Br Med J 1989;298:1152-7.
74. Mills GA, Horn JR. β-blockers and glucose control. Drug Intell Clin Pharm 1985;19:246-51.
75. Bjork S, Mulec H, Johnson SA, Nyberg G, Aurell M. Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy. BMJ 1990;300:904-7.
76. Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993;118:129-38.
77. Stornello M, Valvo EV, Scapellato L. Angiotensin converting enzyme inhibitor in normotensive type II diabetics with persistent mild proteinuria. J Hypertens 1988;7(suppl):S464-6.
78. Rudberg S, Aperia A, Freyschuss U, Persson B. Enalapril reduces microalbuminuria in young normotensive type I (insulin-dependent) diabetic patients irrespective of its hypotensive effect. Diabetologia 1990; 33:470-6.
79. Mathiesen ER, Hommel E, Giese J, Parving HH. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 1991;303:81-7.
80. Cook J, Daneman D, Spino M, Sochett E, Periman K, Balfe JW. Angiotensin converting enzyme inhibitor therapy to decrease microalbuminuria in normotensive children with insulin-dependent diabetes mellitus. J Pediatr 1990;117:39-45.
81. Knowler WC, Kunzelman CL. Population comparisons of the frequency of diabetic nephropathy. In: Mogensen CE, ed. The kidney and hypertension in diabetes mellitus. Boston: Martinus Nijhoff, 1988:25-32.